CHRS

Coherus BioSciences, Inc. (CHRS) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Coherus BioSciences, Inc. is a commercial-stage innovative oncology company. The reporting period reflects a major strategic shift: the company divested its biosimilar business (UDENYCA, YUSIMRY, and CIMERLI franchises), classifying these operations as discontinued operations. The company is now focused exclusively on its oncology portfolio, led by the commercial product LOQTORZI (toripalimab-tpzi) and a pipeline of immuno-oncology candidates.

Key Financial Metrics

Note: Total Debt includes $36.8 million in Term Loans and $228.6 million in Convertible Notes.

Material Changes vs. Prior Period

• Revenue Growth: Continuing operations revenue increased 229% year-over-year, driven by the commercial launch and volume growth of LOQTORZI.
• Discontinued Operations Impact: Q1 2024 included a one-time gain of $153.6 million from the sale of the CIMERLI franchise. Q1 2025 discontinued operations resulted in a loss of $9.2 million, primarily due to the absence of prior-year sale gains and lower revenue from divested assets.
• Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased by $14.2 million ($26.0M vs $40.2M), largely due to the absence of a $6.8 million impairment charge recorded in Q1 2024 related to an out-license asset.
• Research & Development: R&D expenses decreased by $4.1 million ($24.4M vs $28.4M) due to reduced co-development costs and headcount, partially offset by increased spending on pipeline candidates CHS-114 and casdozokitug.

Guidance, Outlook, and Risks

Subsequent Events (Post-March 31, 2025):

• UDENYCA Sale Closing: On April 11, 2025, the company completed the sale of the UDENYCA business to Intas Pharmaceuticals for $483.4 million in upfront cash. The company is eligible for two potential earnout payments of $37.5 million each based on future sales thresholds.
• Debt Repayment: Proceeds from the UDENYCA sale were used to repurchase approximately $170 million of the 2026 Convertible Notes. The company intends to repurchase the remaining ~$60 million by May 15, 2025.
• Royalty Buyout: The company paid $47.7 million to buy out royalty obligations related to UDENYCA.

Outlook: Management expects 2025 revenue from continuing operations to be higher than 2024 due to LOQTORZI growth. Operating expenses are expected to be lower than 2024 due to divestitures and reduced headcount.

Risks and Contingencies:

• Internal Controls: The company identified a material weakness in internal controls related to inventory account reconciliations. While remediation is underway, the specific control was decommissioned with the UDENYCA sale.
• Liquidity: As of March 31, 2025, cash was $82.4 million. Management believes this, combined with proceeds from the UDENYCA sale, is sufficient to fund operations for at least 12 months.
• Competition: LOQTORZI faces significant competition in the nasopharyngeal carcinoma (NPC) market, including recent FDA approval of a competitor (Penpulimab) in April 2025.

Investor Verification Checklist

• Debt Status: Verify the final closing of the $60 million remaining 2026 Convertible Notes repurchase scheduled for May 15, 2025.
• UDENYCA Earnouts: Monitor Intas Pharmaceuticals' performance against the $300 million and $350 million sales thresholds required to trigger the $75 million in potential earnout payments.
• LOQTORZI Commercialization: Track sales volume and market share in the NPC indication, particularly following the April 2025 approval of a competing PD-1 inhibitor.
• Internal Controls: Review future filings for confirmation that the material weakness in inventory controls has been fully remediated or rendered obsolete by the business shift.
• Pipeline Progress: Monitor enrollment and data readouts for clinical candidates casdozokitug (CHS-388) and CHS-114.